Phase 4
N=33
Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection
Pain, Postoperative · Lung Diseases
Bottom Line
View on ClinicalTrials.gov: NCT05144828 ↗Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Change in Visual Analogue Scale (VAS) Pain Score — 4.94; 7.50; 4.57; 6.25 scores on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Intercostal Nerve Cryoablation (Device); Patient-controlled analgesia (PCA) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medical College of Wisconsin
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Visual Analogue Scale (VAS) Pain Score |
4.94; 7.50; 4.57; 6.25; 4.14; 5.44 | — |
| PRIMARY Pain Medication Use |
6.47; 24.38; 8.24; 23.44; 3.00; 19.69 | — |
| SECONDARY M.D. Anderson Symptom Inventory (MDASI) Score |
13.82; 10.88; 40.47; 34.50; 37.53; 25.19 | — |
| SECONDARY Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Score |
0; .13; 8.06; 6.20; 8.33; 3.33 | — |
Summary
This is a single center, single surgeon, prospective, randomized trial examining the addition of Cryo Nerve Block during robot assisted thoracoscopic anatomic lung resection surgery
Eligibility Criteria
Inclusion Criteria
- 18-85 years of age
- Acceptable surgical candidate
- Willing and able to return for scheduled follow-up visits
Exclusion Criteria
- Patients undergoing or requiring conversion to thoracotomy
- Patients with chronic pain syndromes requiring treatment within the last year
- Patients with a history of illicit drug use
- Patients with a history of heavy alcohol use in the last five years as determined by the principal investigator
- Patients currently using opioids
Data sourced from ClinicalTrials.gov (NCT05144828). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.